1704741-11-6
1704741-11-6
Chemical Structure
AZ-PFKFB3-67
- CAS No.: 1704741-11-6
- Formula:C26H25N5O3
- Molecular Weight:455.51
IUPAC Name: (S)-N-(4-((3-cyano-1-((3,5-dimethylisoxazol-4-yl)methyl)-1H-indol-5-yl)oxy)phenyl)pyrrolidine-2-carboxamide
InChIKey: NDIKFKQBWGMLCA-DEOSSOPVSA-N
SMILES: O=C([C@H]1NCCC1)NC2=CC=C(OC3=CC4=C(N(CC5=C(C)ON=C5C)C=C4C#N)C=C3)C=C2
Biological Activity: AZ-PFKFB3-67 is a potent and selective PFKFB3 kinase inhibitor with IC50s of 11, 159 and 1130 nM for PFKFB3, PFKFB2 and PFKFB1, respectively. AZ-PFKFB3-67 reduces MCL-1. AZ-PFKFB3-67 has neuroprotective activity[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
AZ-PFKFB3-67 | 97.03% | AZ-PFKFB3-67 is a potent and selective PFKFB3 kinase inhibitor with IC50s of 11, 159 and 1130 nM for PFKFB3, PFKFB2 and PFKFB1, respectively. AZ-PFKFB3-67 reduces MCL-1. AZ-PFKFB3-67 has neuroprotective activity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
AZ-PFKFB3-67 (Standard) | ≥98% | AZ-PFKFB3-67 (Standard) is the analytical standard of AZ-PFKFB3-67 (HY-101972). This product is intended for research and analytical applications. AZ-PFKFB3-67 is a potent and selective PFKFB3 kinase inhibitor with IC50s of 11, 159 and 1130 nM for PFKFB3, PFKFB2 and PFKFB1, respectively. AZ-PFKFB3-67 reduces MCL-1. AZ-PFKFB3-67 has neuroprotective activity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Boyd S, et al. Structure-Based Design of Potent and Selective Inhibitors of the Metabolic Kinase PFKFB3. J Med Chem. 2015;58(8):3611-3625. [Content Brief]
- [2]. Sneyers F, et al. Intracellular BAPTA directly inhibits PFKFB3, thereby impeding mTORC1-driven Mcl-1 translation and killing MCL-1-addicted cancer cells. Cell Death Dis. 2023 Sep 8;14(9):600. [Content Brief]
- [3]. Madai S, et al. Activation of the hypoxia-inducible factor pathway protects against acute ischemic stroke by reprogramming central carbon metabolism. Theranostics. 2024 Apr 29;14(7):2856-2880. [Content Brief]
Keywords
